The history of Sildenafil presents a complex case for investors in the medicinal sector. While initially a blockbuster success, generating billions, the exclusivity expiration and the subsequent arrival of cheaper alternatives have significantly impacted revenue. This presents questions about the ongoing viability of similar medication developments